SG11201804993RA - Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes - Google Patents
Selective glucagon receptor agonists comprising a chelating moiety for imaging purposesInfo
- Publication number
- SG11201804993RA SG11201804993RA SG11201804993RA SG11201804993RA SG11201804993RA SG 11201804993R A SG11201804993R A SG 11201804993RA SG 11201804993R A SG11201804993R A SG 11201804993RA SG 11201804993R A SG11201804993R A SG 11201804993RA SG 11201804993R A SG11201804993R A SG 11201804993RA
- Authority
- SG
- Singapore
- Prior art keywords
- sanofi
- frankfurt
- international
- aventis
- main
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 22 June 2017 (22.06.2017) WIPO I PCT (10) International Publication Number WO 2017/102613 Al 1111111111111101110101011111010111110 01011010111111110111011111111111110111111 (51) International Patent Classification: A61K 38/22 (2006.01) CO7K 14/575 (2006.01) A61K 38/26 (2006.01) C07K 14/605 (2006.01) (21) International Application Number: PCT/EP2016/080553 (22) International Filing Date: 12 December 2016 (12.12.2016) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 15307000.8 14 December 2015 (14.12.2015) EP (71) Applicant: SANOFI [FR/FR]; 54 me La Boetie, 75008 Paris (FR). (72) Inventors: HAACK, Torsten; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). PLETTENBURG, Oliver; c/o Sanofi-Aventis Deutsch- land GmbH, 65926 Frankfurt am Main (DE). EVERS, An- dreas; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). WAGNER, Michael; c/o Sanofi- Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). BOSSART, Martin; c/o Sanofi-Aventis Deutsch- land GmbH, 65926 Frankfurt am Main (DE). BETRAND, Romain; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt (DE). (74) Agent: ESSLER, Frank; K703, c/o Sanofi-Aventis Deutschland GmbH, Global Intellectual Property Depart- ment, 65926 Frankfurt (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) W O 20 17 / 10 26 13 Al (54) Title: SELECTIVE GLUCAGON RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING PUR- POSES (57) : The present invention relates to exendin-4 peptide analogues which selectively bind and activate the glucagon recept- or and comprise a chelating moiety capable of binding a metal ion and their use, for example in PET imaging.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15307000 | 2015-12-14 | ||
| PCT/EP2016/080553 WO2017102613A1 (en) | 2015-12-14 | 2016-12-12 | Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201804993RA true SG11201804993RA (en) | 2018-07-30 |
Family
ID=55129466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201804993RA SG11201804993RA (en) | 2015-12-14 | 2016-12-12 | Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11046743B2 (en) |
| EP (1) | EP3389697B1 (en) |
| JP (1) | JP6986516B2 (en) |
| KR (1) | KR20180086270A (en) |
| CN (1) | CN108697767B (en) |
| AU (1) | AU2016372245B2 (en) |
| BR (1) | BR112018011892A2 (en) |
| CA (1) | CA3008052C (en) |
| DK (1) | DK3389697T3 (en) |
| ES (1) | ES2846023T3 (en) |
| HR (1) | HRP20210073T1 (en) |
| HU (1) | HUE053079T2 (en) |
| IL (1) | IL259961A (en) |
| LT (1) | LT3389697T (en) |
| MX (1) | MX2018007323A (en) |
| PL (1) | PL3389697T3 (en) |
| PT (1) | PT3389697T (en) |
| RU (1) | RU2018125958A (en) |
| SG (1) | SG11201804993RA (en) |
| SI (1) | SI3389697T1 (en) |
| WO (1) | WO2017102613A1 (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004043153B4 (en) | 2004-09-03 | 2013-11-21 | Philipps-Universität Marburg | Invention relating to GLP-1 and exendin |
| AU2006249869A1 (en) * | 2005-05-26 | 2006-11-30 | Bristol-Myers Squibb Company | N-terminally modified GLP-1 receptor modulators |
| US20100022457A1 (en) | 2006-05-26 | 2010-01-28 | Bristol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
| UA116217C2 (en) * | 2012-10-09 | 2018-02-26 | Санофі | Exendin-4 derivatives as dual glp1/glucagon agonists |
| RU2652783C2 (en) * | 2012-12-21 | 2018-05-03 | Санофи | Dual glp1/gip or trigonal glp1/gip/glucagon agonists |
| US9932381B2 (en) * | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
-
2016
- 2016-12-12 RU RU2018125958A patent/RU2018125958A/en not_active Application Discontinuation
- 2016-12-12 LT LTEP16819291.2T patent/LT3389697T/en unknown
- 2016-12-12 WO PCT/EP2016/080553 patent/WO2017102613A1/en active Application Filing
- 2016-12-12 ES ES16819291T patent/ES2846023T3/en active Active
- 2016-12-12 US US16/061,421 patent/US11046743B2/en active Active
- 2016-12-12 PL PL16819291T patent/PL3389697T3/en unknown
- 2016-12-12 KR KR1020187019959A patent/KR20180086270A/en active IP Right Grant
- 2016-12-12 SG SG11201804993RA patent/SG11201804993RA/en unknown
- 2016-12-12 HU HUE16819291A patent/HUE053079T2/en unknown
- 2016-12-12 DK DK16819291.2T patent/DK3389697T3/en active
- 2016-12-12 CN CN201680081731.0A patent/CN108697767B/en active Active
- 2016-12-12 BR BR112018011892-3A patent/BR112018011892A2/en not_active Application Discontinuation
- 2016-12-12 CA CA3008052A patent/CA3008052C/en active Active
- 2016-12-12 SI SI201631056T patent/SI3389697T1/en unknown
- 2016-12-12 JP JP2018549616A patent/JP6986516B2/en active Active
- 2016-12-12 AU AU2016372245A patent/AU2016372245B2/en active Active
- 2016-12-12 EP EP16819291.2A patent/EP3389697B1/en active Active
- 2016-12-12 MX MX2018007323A patent/MX2018007323A/en unknown
- 2016-12-12 PT PT168192912T patent/PT3389697T/en unknown
-
2018
- 2018-06-12 IL IL259961A patent/IL259961A/en unknown
-
2021
- 2021-01-14 HR HRP20210073TT patent/HRP20210073T1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| LT3389697T (en) | 2021-02-10 |
| PT3389697T (en) | 2021-01-22 |
| CA3008052A1 (en) | 2017-06-22 |
| CA3008052C (en) | 2024-01-02 |
| JP2019508480A (en) | 2019-03-28 |
| MX2018007323A (en) | 2019-01-10 |
| KR20180086270A (en) | 2018-07-30 |
| JP6986516B2 (en) | 2021-12-22 |
| BR112018011892A2 (en) | 2018-12-04 |
| EP3389697A1 (en) | 2018-10-24 |
| DK3389697T3 (en) | 2021-01-11 |
| RU2018125958A (en) | 2020-01-20 |
| US11046743B2 (en) | 2021-06-29 |
| RU2018125958A3 (en) | 2020-06-09 |
| AU2016372245B2 (en) | 2020-07-16 |
| SI3389697T1 (en) | 2021-02-26 |
| US20200262885A1 (en) | 2020-08-20 |
| AU2016372245A1 (en) | 2018-07-26 |
| WO2017102613A1 (en) | 2017-06-22 |
| CN108697767A (en) | 2018-10-23 |
| IL259961A (en) | 2018-07-31 |
| CN108697767B (en) | 2022-04-15 |
| PL3389697T3 (en) | 2021-04-19 |
| ES2846023T3 (en) | 2021-07-28 |
| HRP20210073T1 (en) | 2021-04-30 |
| HUE053079T2 (en) | 2021-06-28 |
| EP3389697B1 (en) | 2020-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908813QA (en) | Anti-sirp alpha antibodies | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201901548SA (en) | Anti-tim-3 antibodies and use thereof | |
| SG11201900501RA (en) | Cannabis composition | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201804086VA (en) | Methods and compositions for nucleic acid analysis | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201804161VA (en) | Compositions comprising bacterial strains | |
| SG11201807279QA (en) | Binding proteins and methods of use thereof | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201805950UA (en) | Self-assembled nanostructures and separation membranes comprising aquaporin water channels and methods of making and using them | |
| SG11201909520VA (en) | Rna for treatment of autoimmune diseases | |
| SG11201408051VA (en) | Cho expression system | |
| SG11201810429UA (en) | Anti-cd19 antibody formulations | |
| SG11201809341PA (en) | Mobile robot | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201806267QA (en) | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201807255YA (en) | Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones | |
| SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
| SG11201908472VA (en) | Compositions and methods for activating nk cells | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201807549TA (en) | Combination of a cxcr4 antagonist and an immune checkpoint inhibitor | |
| SG11201906682YA (en) | Glucagon receptor binding proteins and methods of use thereof |